Proton therapy for Hodgkin lymphoma

TY - CHAP

T1 - Proton therapy for Hodgkin lymphoma

AU - Hoppe, Bradford

AU - Slopsema, Roelf

AU - Specht, Lena

PY - 2011

Y1 - 2011

N2 - Due to the high cure rates in Hodgkin lymphoma (HL) patients treated with combined-modality treatment, the subsequent late toxicities from treatment become increasingly important. Survivors of HL are at high risk for developing and dying from secondary cancers and heart diseases as a consequence of their treatment. Limiting the radiation to normal tissues using techniques that allow smaller radiation fields and lowering the total dose has already shown some improvement in reducing the subsequent late effects from radiotherapy. Proton therapy may also help decrease the amount of normal tissue irradiated, thereby reducing the subsequent late effects from radiotherapy.

AB - Due to the high cure rates in Hodgkin lymphoma (HL) patients treated with combined-modality treatment, the subsequent late toxicities from treatment become increasingly important. Survivors of HL are at high risk for developing and dying from secondary cancers and heart diseases as a consequence of their treatment. Limiting the radiation to normal tissues using techniques that allow smaller radiation fields and lowering the total dose has already shown some improvement in reducing the subsequent late effects from radiotherapy. Proton therapy may also help decrease the amount of normal tissue irradiated, thereby reducing the subsequent late effects from radiotherapy.

U2 - 10.1007/978-3-540-78944-4

DO - 10.1007/978-3-540-78944-4

M3 - Book chapter

SN - 978-3-540-78455-5

SP - 197

EP - 203

BT - Radiotherapy for Hodgkin lymphoma

A2 - Specht, Lena

A2 - Yahalom, Joachim

PB - Springer

CY - Berlin

ER -